Shareholder Tools

Genmab News

Genmab News

In accordance with legal requirements, notifications regarding Managers’ Transactions are published in the database of the Danish Financial Supervisory Authority and can be accessed at the following link: https://oasm.dfsa.dk/uk/frontpage.aspx. As a general rule, Genmab no longer issues Company Announcements concerning these transactions.

News Category

Year

Date	Title	View
Aug 14, 2019	Genmab Announces Financial Results for the First Half of 2019 and Updates 2019 Financial Guidance	190814_CA40_Q2 2019 Interim Report
Jul 23, 2019	Genmab A/S has published its Articles of Association	Articles of Association - July 17 2019 II (UK)
Jul 23, 2019	Genmab Announces the Closing of Over-Allotment Option in Initial Public Offering of American Depositary Shares (ADSs) in the United States and Registration of Capital Increase	190723_CA39_Overallotment Closing
Jul 22, 2019	Genmab A/S has published its Articles of Association	Articles of Association - 17 July 2019 UK
Jul 22, 2019	Genmab Announces the Completion of its Initial Public Offering of American Depositary Shares (ADSs) in the United States and Registration of Capital Increase	190722_CA38_Closing
Jul 19, 2019	Major Shareholder Announcement	190719_CA37_Major Shareholder Blackrock Increase
Jul 19, 2019	Genmab Announces Full Exercise of Underwriters’ Over-Allotment Option in Initial Public Offering	190719_CA36_over-allotment option
Jul 19, 2019	Genmab Announces Submission of Extension of Marketing Authorization to European Medicines Agency for Subcutaneous Formulation of Daratumumab	190719_i09_Dara SC EMA Submission
Jul 17, 2019	Genmab Prices its Initial Public Offering of American Depositary Shares (ADSs) in the United States	190718_CA35_Pricing
Jul 16, 2019	Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2019	190716_CA34_Dara Q2 Sales
Jul 12, 2019	Genmab Announces Submission of Biologics License Application to U.S. FDA for Subcutaneous Formulation of Daratumumab	190712_CA33_Dara SC FDA Submission
Jul 12, 2019	Genmab and BliNK Biomedical Enter into Commercial License Agreement	190712_i08_BliNK
Jul 09, 2019	Genmab Commences Public Offering of American Depositary Shares (ADSs) in the United States	190709_CA32_Launch Announcement
Jul 08, 2019	Genmab Announces Positive Topline Results in the Phase II GRIFFIN Study of Transplant Eligible, Newly Diagnosed Patients with Multiple Myeloma Treated with Daratumumab in Combination with Lenalidomide, Bortezomib, and Dexamethasone	190708_CA31_GRIFFIN Data
Jun 27, 2019	Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma	190627_CA30_MAIA Approval
Jun 26, 2019	Genmab A/S has published its Articles of Association	Articles of Association - June 25 2019 (UK)
Jun 25, 2019	Major Shareholder Announcement	190625_CA_29_Major Shareholder Announcement Blackrock
Jun 25, 2019	Capital Increase in Genmab as a Result of Employee Warrant Exercise	190625_CA28_Warrant Exercise
Jun 19, 2019	Major Shareholder Announcement	190619_CA_27_Major Shareholder Announcement Blackrock
Jun 19, 2019	Major Shareholder Announcement	190619_CA_26_Major_Shareholder_Blackrock
Jun 13, 2019	Genmab A/S has published its Articles of Association	Articles of Association - June 6, 2019 (UK)
Jun 11, 2019	Genmab Signs Agreement with Janssen for Next-Generation CD38 Antibody, HexaBody®-CD38	190611_CA25_HexaBody-CD38
Jun 06, 2019	Grant of Restricted Stock Units and Warrants to Employees in Genmab	190606_CA24_Warrant Grant
May 30, 2019	U.S. FDA Grants Priority Review for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma	190530_CA23_CASSIOPEIA PDUFA priority review
May 28, 2019	Genmab Files Registration Statement in the United States for a Proposed Public Offering of American Depositary Shares (ADSs) and Applies for Listing of the ADSs on Nasdaq	190528_CA22_Registration Statement Filing

Shareholder Tools